Identification of integrins α6 and β7 as c-Jun- and transformation-relevant genes in highly invasive fibrosarcoma cells

International Journal of Cancer

Volumn 125, Issue 5, 2009, Pages 1065-1073

  Kielosto, Mari ^a   Nummela, Pirjo ^a   Järvinen, Kristiina ^a   Yin, Miao ^a   Hölttä, Erkki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

c Jun; Fibrosarcoma cells; Integrin 6 1; Invasion; S adenosylmethionine decarboxylase

Indexed keywords

ADENOSYLMETHIONINE DECARBOXYLASE; ALPHA6 INTEGRIN; BETA7 INTEGRIN; CATHEPSIN L; MATRIGEL; PROTEIN C JUN; SHORT HAIRPIN RNA; THYMOSIN BETA4; BETA INTEGRIN; COLLAGEN; LAMININ; MESSENGER RNA; PROTEOGLYCAN; S ADENOSYLMETHIONINE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR MARKER; VERY LATE ACTIVATION ANTIGEN 6;

ANIMAL CELL; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CELL STRAIN 3T3; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROSARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CELL MOTION; CELL TRANSFORMATION; DNA MICROARRAY; DRUG COMBINATION; ENZYME IMMUNOASSAY; ENZYMOLOGY; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

ADENOSYLMETHIONINE DECARBOXYLASE; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; COLLAGEN; DRUG COMBINATIONS; FIBROBLASTS; FIBROSARCOMA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTEGRIN ALPHA6BETA1; INTEGRIN BETA CHAINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LAMININ; MICE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; S-ADENOSYLMETHIONINE; TUMOR MARKERS, BIOLOGICAL;

EID: 67650076573     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24391     Document Type: Article

References (51)

1. Paasinen-Sohns A, Kielosto M, Kaariainen E, Eloranta T, Laine A, Janne OA, Birrer MJ, Holtta E. c-Jun activation-dependent tumorigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylase. J Cell Biol 2000;151:801-10.
2. Nummela P, Yin M, Kielosto M, Leaner V, Birrer MJ, Holtta E. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res 2006;66:701-12.
3. Porter CW, Herrera-Ornelas L, Pera P, Petrelli NF, Mittelman A. Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 1987;60:1275-81.
4. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A, Corti A. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000;60:28-34.
5. Casero RA, Jr, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6:373-90.
6. Angel P, Karin M. The role of Jun. Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
7. Vogt PK. Jun, the oncoprotein. Oncogene 2001;20:2365-77.
8. Tessari G, Ferrara C, Poletti A, Dubrovich A, Corsini A, Del Favero G, Naccarato R. The expression of proto-oncogene c-jun in human pancreatic cancer. Anticancer Res 1999;19:863-7.
9. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002;21:7680-9.
10. Suto R, Tominaga K, Mizuguchi H, Sasaki E, Higuchi K, Kim S, Iwao H, Arakawa T. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther 2004;11:187-93.
11. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, Stern MH, Aurias A. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007;11:361-74.
12. Paasinen-Sohns A, Holtta E. Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase/Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression. Oncogene 1997;15:1953-66.
13. Shaulian E, Karin M AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-6.
14. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
15. Bos TJ, Margiotta P, Bush L, Wasilenko W. Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun overexpression. Int J Cancer 1999;81:404-10.
16. Kraemer M, Tournaire R, Dejong V, Montreau N, Briane D, Derbin C, Binetruy B. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ 1999;10:193-200.
17. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004;96:683-96.
18. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002;21:7077-91.
19. Black EJ, Clair T, Delrow J, Neiman P, Gillespie DA. Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-jun. Oncogene 2004;23:2357-66.
20. Ozanne BW, Spence HJ,McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007;26:1-10.
21. Kielosto M, Nummela P, Katainen R, Leaner V, Birrer MJ, Holtta E. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun. Cancer Res 2004;64:3772-9.
22. Kaariainen E, Nummela P, Soikkeli J, Yin M, Lukk M, Jahkola T, Virolainen S, Ora A, Ukkonen E, Saksela O, Holtta E. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol 2006;210:181-91.
23. Soikkeli J, Lukk M, Nummela P, Virolainen S, Jahkola T, Katainen R, Harju L, Ukkonen E, Saksela O, Holtta E. Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol 2007;213:180-9.
24. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005;25:220-32.
25. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107:643-54.
26. Ravanko K, Jarvinen K, Helin J, Kalkkinen N, Holtta E. Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts. Cancer Res 2004;64:8831-8.
27. Draghici S, Khatri P, Eklund AC, Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006;22:101-9.
28. Holtta E, Sistonen L, Alitalo K. The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells. J Biol Chem 1988;263:4500-7.
29. Ishidoh K, Kominami E. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem Biophys Res Commun 1995;217:624-31.
30. Rodrigues NR, Theodosiou AM, Nesbit MA, Campbell L, Tandle AT, Saranath D, Davies KE. Characterization of Ngef, a novel member of the Dbl family of genes expressed predominantly in the caudate nucleus. Genomics 2000;65:53-61.
31. Toft DJ, Rosenberg SB, Bergers G, Volpert O, Linzer DI. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc Natl Acad Sci USA 2001;98:13055-9.
32. Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LM, Birrer MJ. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004;2:305-14.
33. Dhar A, Hu J, Reeves R, Resar LM, Colburn NH. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 2004;23:4466-76.
34. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999;248:44-57.
35. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998;36:85-91.
36. Todorovicc V, Chen CC, Hay N, Lau LF. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol 2005;171:559-68.
37. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-38.
38. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
39. Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev 2005;24:413-23.
40. Wilhelmsen K, Litjens SH, Sonnenberg A. Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis. Mol Cell Biol 2006;26:2877-86.
41. Rabinovitz I, Nagle RB, Cress AE. Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 1995;13:481-91.
42. Chung J, Mercurio AM. Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol Cells 2004;17:203-9.
43. Nishida K, Kitazawa R, Mizuno K, Maeda S, Kitazawa S. Identification of regulatory elements of human alpha 6 integrin subunit gene. Biochem Biophys Res Commun 1997;241:258-63.
44. Ramos DM, Cheng YF, Kramer RH. Role of laminin-binding integrin in the invasion of basement membrane matrices by fibrosarcoma cells. Invasion Metastasis 1991;11:125-38.
45. Lin CS, Zhang K, Kramer R. Alpha 6 integrin is up-regulated in step increments accompanying neoplastic transformation and tumorigenic conversion of human fibroblasts. Cancer Res 1993;53:2950-3.
46. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-9.
47. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, Yamada A, Maeda A, Matsuno F, Hata H, Suzuki A, Imagawa S, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006;66:812-9.
48. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAd-CAM-1. Cell 1993;74:185-95.
49. Agace WW, Higgins JM, Sadasivan B, Brenner MB, Parker CM. T-lymphocyte-epithelial-cell interactions: integrin alpha(E)(CD103)beta(7), LEEP-CAM and chemokines. Curr Opin Cell Biol 2000; 12:563-8.
50. Strauch UG, Mueller RC, Li XY, Cernadas M, Higgins JM, Binion DG, Parker CM. Integrin alpha E(CD103)beta 7 mediates adhesion to intestinal microvascular endothelial cell lines via an E-cadherin-independent interaction. J Immunol 2001;166:3506-14.
51. Leaner VD, Kinoshita I, Birrer MJ. AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene 2003;22:5619-29.